Epic Sciences, Inc., a San Diego, CA-based private diagnostics company that designs and develops products and offerings to personalize and advance the treatment and management of cancer, has expanded the available credit under its existing credit facility with Silicon Valley Bank (SVB).
The amended agreement increases the available capacity of the facility from $5 million to $15m and has extended the maturity by 27 months to April 1, 2019.
The availability of additional capital provides Epic Sciences the option to accelerate the expansion of its research capabilities and product development efforts.
Led by Murali Prahalad, Ph.D., president and CEO, Epic Sciences develops technology that enables the comprehensive characterization of circulating tumor cells (CTCs) from a liquid biopsy to inform therapy selection, including combination therapies, and the detection of early signs of drug resistance.
FinSMEs
01/06/2015